RG
VIRX icon

Redmile Group’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Redmile Group’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-119
Closed -$64K – 66
2014
Q4 		$64K Buy
+119
New +$53.6K 0.01% 54
2014
Q3 		– Sell
-48
Closed -$65K – 66
2014
Q2 		$65K Hold
48
– – 0.01% 47
2014
Q1 		$66K Sell
48
-119
-71% -$138K 0.01% 55
2013
Q4 		$166K Buy
+167
New +$173K 0.02% 55

Other funds holding VIRX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Redmile Group's VIRX Position: Q1 2015 in Review

Redmile Group sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q1 2015, closing a stake of 119 shares — an estimated $64K sold.

Redmile Group first reported a position in VIRX in Q4 2013 and held it in 4 quarters. The position peaked at $166K in Q4 2013. 83 funds tracked by Wall St. Rank hold VIRX as of Q1 2015.

  • Redmile Group reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q1 2015 after selling out during the quarter.
  • Redmile Group sold 119 Viracta Therapeutics, Inc. Common Stock shares in Q1 2015, an estimated $64K.
  • Redmile Group first reported a position in Viracta Therapeutics, Inc. Common Stock in Q4 2013 and held it in 4 quarters.
  • Redmile Group's Viracta Therapeutics, Inc. Common Stock position peaked at $166K in Q4 2013.
  • 83 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q1 2015.

Based on Redmile Group's 13F filing for Q1 2015, filed 18 May 2015.